



Mordue, K. E., Hawley, B. R., Satchwell, T. J., & Toye, A. M. (2017). CD47 surface stability is sensitive to actin disruption prior to inclusion within the band 3 macrocomplex. *Scientific Reports*, 7, [2246].
<https://doi.org/10.1038/s41598-017-02356-1>

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.1038/s41598-017-02356-1](https://doi.org/10.1038/s41598-017-02356-1)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Nature at <https://www.nature.com/articles/s41598-017-02356-1>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Supplement

CD47 surface stability is sensitive to actin disruption prior to inclusion within the band 3 macrocomplex

Kathryn E. Mordue¹, Bethan R. Hawley^{1,2,3}, Timothy J. Satchwell^{1,2,3} & Ashley M. Toye^{1,2,3}

¹School of Biochemistry, Medical Sciences Building, University Walk, Bristol, UK;

²Bristol Institute of Transfusion Sciences, NHSBT, Filton, UK

³NIHR Blood and Transplant Unit in Red Blood Cell products at the University of Bristol.

Correspondenc

Supplementary Figure S1




Figure S1. K562 cells and SH-SY5Y cells express CD47 isoform 2 and isoforms 3 and 4, but CD47 isoforms 3 and 4 were only detected at the surface of SH-SY5Y cells. (A) Cells were lysed and separated by SDS-PAGE (10^6 cells/lane). Western blots were then probed with anti-CD47out1 (Total), anti-CD47 isoform 2 or anti-CD47 isoforms 3 and 4 (protein band indicated by *) ($n=2$). Total cell, and cell surface immunoprecipitations followed by internal immunoprecipitations, were carried out on 5 - 10×10^6 K562 cells (B) and SH-SY5Y cells (C). The eluates were separated by SDS-PAGE against K562 and SH-SY5Y cell lysates (10^6 cells/lane). Western blots were then probed with anti-CD47 isoform 2 or anti-CD47 isoforms 3 and 4 ($n=2$).

Supplementary Figure S2.





Figure S2 The hallmarks of protein 4.2 deficiency are recapitulated following shRNA-mediated knockdown of protein 4.2 via lentiviral transduction.

Erythroblasts were transduced with lentiviral pLKO.1 protein 4.2 shRNA1, or a scramble shRNA control, as detailed in the methods. (A and C) 1.5×10^6 protein 4.2 deficient and scramble control erythroblasts were incubated with Hoechst for 45 minutes at 37°C, to separate erythroblasts from reticulocytes and nuclei, and fixed in 1% PFA and 0.0075% glutaraldehyde²⁴ prior to labelling with BRIC32 (CD47) or BRIC222 (CD44) for 30 minutes at 4°C. The cells were then incubated with an APC-conjugated monoclonal rat anti-mouse IgG1 secondary, and membrane protein expression was assessed by flow cytometry. (A) Every 24 hours during differentiation expression of CD47 and CD44 on erythroblasts was assessed by flow cytometry (n=3 for each time point). (B) Filtered reticulocytes generated from *in vitro* cultured protein 4.2 deficient erythroblasts compared to Scramble shRNA control erythroblast, were lysed and separated by SDS-PAGE (1.8×10^5 reticulocytes/lane). Western blots were probed with rabbit anti-C terminal band 3 antibody (YNTU), BRIC273 (anti-protein 4.2), BRIC222 (anti-CD44), anti-CD47 (CD47out1) and anti-GAPDH as a loading control (n=2). (C) Average protein expression of CD47 and CD44 on reticulocytes between 96-144 hours post-differentiation (Average MFI as a % of the scramble control \pm SEM (n=3 at each time point), *** $p \leq 0.001$; ** $p \leq 0.01$ using the Students *T* test). Emissions from 10,000 events were detected using a MACSQuant Analyser 10 flow cytometer and data was analysed using FlowJo version 10.

Supplementary Figure S3




Figure S3. Inhibition of CD47 endocytosis in K562 cells. 1×10^6 K562 cells were incubated with MiTMAB (30 μ M), Dynasore (80 μ M), Pitstop 2 (30 μ M), Sucrose (15mM) or a DMSO control for 20 minutes at 37°C. K562 cells were then stained with (A) BRIC32 (anti-CD47), or (B) P5D2 (anti- β_1 Integrin) followed by APC-conjugated monoclonal IgG1 anti-mouse secondary antibody, before being assessed by flow cytometry (Average MFI as a % of the DMSO controls \pm SD (n=4); *** $p \leq 0.001$; ** $p \leq 0.01$, * $p \leq 0.05$ using the Students *T* test). 10,000 events were detected using a MACSQuant Analyser 10 flow cytometer and data was analysed using FlowJo version 10.

Supplemental Table 1. Summary of the proteomic profile of peptides detected following BRIC126 immunoprecipitations (IP) in K562 cells, EXP, T0 and T48 erythroblasts, and mature erythrocytes (RBCs). The total BRIC126 IP peptides and IgG peptides are shown alongside the ratio total/IgG. Clean total (Tot) peptides are underlined and bold. * Indicates no ratio due to absence of IgG control peptides . Peptides detected in the BRIC126 IP that are less than 2-fold enriched, compared to the isotype control (IgG) are highlighted in grey.

Accession Number	Protein Description	K562 cells			EXP			T0			T48			Mature RBCs		
		Tot	IgG	Ratio	Tot	IgG	Ratio	Tot	IgG	Ratio	Tot	IgG	Ratio	Tot	IgG	Ratio
P60709	Actin, cytoplasmic 1	71	33	2.2	242	109	2.2	194	114	1.7	18	42	0.4	155	139	1.1
P61158	Actin-related protein 3	<u>5</u>	-	*	8	6	1.3	13	6	2.2	-	-	-	2	2	1
O43707	Alpha-actinin-4	<u>8</u>	-	*	59	20	3.0	86	45	2.0	-	-	-	25	29	0.9
Q562R1	β -actin like protein 2	14	3	4.7	45	19	2.4	42	25	1.7	-	-	-	35	39	0.9
Q96C19	EF hand containing protein D2	<u>7</u>	-	*	12	3	4	15	6	2.5	-	-	-	<u>6</u>	-	*
P15311	Ezrin	12	6	2	-	-	-	-	-	-	-	-	-	6	14	0.4
P47756	F-actin capping protein subunit β	7	1	7	17	6	2.8	12	9	1.3	-	-	-	3	3	1
P21333	Filamin A	42	15	2.8	54	6	9	17	25	0.7	-	-	-	20	62	0.3
Q08722	Leucocyte surface antigen, CD47	6	1	6	7	2	3.5	8	4	2	6	5	1.2	14	6	2.3
Q9UHB6	LIMA1	-	-	-	7	2	3.5	27	5	5.4	-	-	-	3	5	0.6
P26038	Moesin	22	7	3.1	3	1	3	3	5	0.6	2	7	0.3	4	23	0.2
O94832	Myosin-Id	12	2	6	20	12	1.7	34	19	1.8	-	-	-	20	37	0.5
P35579	Myosin-9	228	72	3.2	374	166	2.3	224	185	1.2	5	17	0.3	302	410	0.7
P35580	Myosin-10	154	37	4.2	240	132	1.8	204	172	1.2	2	7	0.3	196	284	0.7

P12829	Myosin light chain 4	13	2	6.5	8	1	8	26	5	5.2	1	1	1	19	25	0.8
P35241	Radixin	10	5	2	-	-	-	-	-	-	-	-	-	-	-	-
P02549	Spectrin α chain, erythrocyte	-	-	-	<u>19</u>	-	*	30	27	1.1	1	5	0.2	-	-	-
P11277	Spectrin β chain, erythrocyte	-	-	-	9	1	9	27	23	1.2	-	-	-	-	-	-
Q9NYL9	Tropomodulin-3	-	-	-	<u>8</u>	-	*	8	2	4	-	-	-	2	1	2
P06753	Tropomyosin α -3 chain	9	1	9	3	3	1	<u>5</u>	-	*	-	-	-	8	5	1.6
Q71U36	Tubulin α -1A chain	25	17	1.5	<u>14</u>	-	*	<u>23</u>	-	*	11	28	0.4	-	-	-
P62988	Ubiquitin	19	3	6.3	2	2	1	4	3	1.3	7	9	0.8	4	20	0.2
P68036	Ubiquitin-conjugated enzyme E2 L3	14	5	2.8	-	-	-	-	-	-	-	-	-	<u>4</u>	-	*
P08670	Vimentin	-	-	-	<u>5</u>	-	*	<u>2</u>	-	*	-	-	-	10	13	0.8